ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE

August 27, 2019

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

nahaleh naraqi
August 28, 2024

Author:

Acteropharma
Nahale Naraghi honors National Doctors Day in Iran, coinciding with Avicenna’s birthday.
WhatsApp Image 2024-08-27 at 13.38.40
August 27, 2024

Author:

Acteropharma
Nahale Naraghi honors Pharmacist Day with a special message of gratitude, recognizing the essential role pharmacists play in advancing healthcare and supporting patient well-being
iranian-gastro-intestinal-min
June 1, 2024

Author:

Acteropharma
The first seminar on Gastrointestinal cancer updates was held on May 23 , 2024  in Sari city with the presence of great professors of hematology and oncology, radio-oncology specialists, gastroenterology specialists, etc.